Resources

Instant Insights – CRISPR

Home | Resources

Prescriber Perceptions around CRISPR in 2023

Four years ago, InCrowd assessed the awareness among physicians of nucleic acid-based therapies, their mechanisms of action, and their current and future promise.
In considering the 2019 research, InCrowd wanted to understand any change in awareness of these therapies and then examine specific perceptions around CRISPR. This research reflects the comparisons of awareness between 2019 and 2023 of nucleic acid-based therapies with a specific focus on CRISPR.

Our 2023 report includes responses from over 100 qualified US-based healthcare professionals (HCPs) familiar with the therapies considered in the research.

Explore respondents’:

  • Awareness of CRISPR and mRNA
  • Optimism and concerns regarding the widespread use of CRISPR
  • Comfort level recommending and administering CRISPR to patients

Get our key takeaways. Download the report today.

Please fill out the form below to access this content

Name(Required)
Consent
This field is for validation purposes and should be left unchanged.

Related Resources

2023 Post-ESMO Excitement Report 

2023 Post-ESMO Excitement Report 

What Doctors thought of this year's ESMO Event Reaching European attendees, our 2023 Post-ESMO report sought to understand the event’s areas of greatest interest. 95 European oncologists and haematologist-oncologists shared with us the findings and developments they...

read more
Instant Insights – Weight Loss Drugs

Instant Insights – Weight Loss Drugs

Prescriber Perspectives on Weight Loss Drugs in 2023 Examine how healthcare professionals (HCPs) view and prescribe weight loss drugs currently on the market in our new Instant Insights report. Fielded in a single day, this report includes responses from 100 qualified...

read more
Post-ASCO Excitement Report

Post-ASCO Excitement Report

Physician Perspectives on the 2023 ASCO Annual Meeting Curious what doctors thought about ASCO? Nearly 100 oncologists and hematologist oncologists shared with us the findings and developments they were most excited about. Check-out our 2023 Post-ASCO report to...

read more